Focal Treatments for Prostate Cancer
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and medical necessity determinations for focal therapy modalities (eg, focal laser ablation, HIFU, cryoablation, RFA, photodynamic therapy, irreversible electroporation) used to treat localized prostate cancer for Blue Cross Blue Shield - Rhode Island members.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Coverage Stance by Product
Policy statement summarized by product:
Evidence assessment / Medical necessity conclusion
Summary of evidence-based stance
All focal therapy modalities for the treatment of localized prostate cancer are excluded from coverage. For Medicare Advantage plans, use of any focal therapy modality to treat patients with localized prostate cancer is not covered. For Commercial products, use of any focal therapy modality to treat patients with localized prostate cancer is considered not medically necessary. These stances are based on the policy conclusion that current evidence is insufficient to determine the effects of these technologies on health outcomes.
The following procedure codes are explicitly listed as not covered for Medicare Advantage Plans and not medically necessary for Commercial Products: 0655T, 0739T, 55880, and 55877. When no specific CPT code applies to a provided focal procedure, use the unlisted male genital system code 55899.
For commercial products the policy determines focal therapy to be not medically necessary because the available evidence is heterogeneous, limited in quality, and insufficient to demonstrate an improvement in net health outcome compared with standard management. Reported studies have short follow-up, small sample sizes, and lack prospective comparative trials versus radical prostatectomy, external-beam radiotherapy, or active surveillance, preventing conclusions that these modalities improve overall survival, disease-specific survival, or other key clinical outcomes.
Evidence is insufficient across focal ablation techniques — including focal laser ablation, high-intensity focused ultrasound (HIFU), cryoablation, radiofrequency ablation (RFA), photodynamic therapy, irreversible electroporation (IRE), and magnetic nanoparticle ablation — to support their routine use. The literature is highly heterogeneous, outcomes and methods are inconsistently reported, and prospective comparative evidence versus standard treatments is largely absent. Consequently, the policy treats these specified focal procedures as not covered / not medically necessary.
Coding and Billing
| 0655T | Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging |
| 0739T | Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation |
| 55880 | Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance |
| 55877 | Ablation, irreversible electroporation, prostate, 1 or more tumors, including imaging guidance, percutaneous (New Code Effective 1/1/2026) |
| 55899 | Unlisted procedure, male genital system |
Provider Actions, Billing Rules, and Documentation
Prior authorization: Not applicable — verify member contract
Prior authorization: Not applicable for this policy. Check the member’s benefit booklet or contract, because benefits and any prior authorization requirements may vary by group or subscriber agreement.
Coding and coverage: listed codes not covered; use 55899 when no CPT
The following CPT codes are explicitly stated as not covered for Medicare Advantage and not medically necessary for Commercial products; claims billed with these codes are at risk for denial: 0655T, 0739T, 55880, 55877. The policy also directs use of unlisted procedure code 55899 when no specific CPT exists for the service provided.
- 0655T — Transperineal focal laser ablation of malignant prostate tissue
- 0739T — Ablation of malignant prostate tissue by magnetic field induction
- 55880 — Ablation of malignant prostate tissue, transrectal, with HIFU
- 55877 — Ablation, irreversible electroporation, prostate, percutaneous
- 55899 — Unlisted procedure, male genital system (use when no specific CPT assigned)
Step therapy: Not applicable
Step therapy: Not applicable. There are no step therapy requirements specified in the medical criteria for this policy.
Submit correct codes and follow policy coding guidance
Follow policy instructions and coding guidance when submitting claims for focal therapies; see the list of not covered/not medically necessary codes to avoid claim denials.
Verify benefits in the member’s Benefit Booklet / Evidence of Coverage
Benefits and coverage can differ by group or contract. Refer to the member’s Benefit Booklet, Evidence of Coverage, or Subscriber Agreement to determine whether focal therapies are covered under a specific plan.
Use CPT 55899 for unlisted male genital procedures
When a specific CPT code for a focal prostate procedure is not available or assigned, bill the service with CPT 55899 (Unlisted procedure, male genital system) as directed by the policy.
High denial risk — focal therapies not covered / not medically necessary
Coverage denial risk: Use of any focal therapy modality to treat localized prostate cancer is not covered for Medicare Advantage plans and is not medically necessary for Commercial products; such claims are therefore at risk for denial.
Background and Rationale
Focal treatment aims to ablate one or more selected cancerous lesions within the prostate—typically the index lesion—to reduce tumor burden while attempting to preserve urinary, sexual, and rectal function compared with whole-gland therapies. These approaches rely on targeted probe placement and energy delivery to the tumor volume using a variety of energy sources. However, methods for selecting lesions, which lesions to treat, and the technical delivery of energy are not standardized, and the evidence does not identify which, if any, focal technique provides superior functional or long-term oncologic outcomes.
Definitions and Modalities
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.